BOSTON--(BUSINESS WIRE)--Sept. 14, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) presented yesterday new data further elucidating talabostat's ability to stimulate key cytokines known to play an important role in immunostimulation--the enhancement of the body's natural defenses against cancer. This study was conducted in the laboratory of Dr. Charles Dinarello, a Professor of Medicine at the University of Colorado School of Medicine. The data were presented at the American Association of Cancer Research Annual Meeting (AACR) International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Chicago, IL.
